FDA approves brain stem cell transplant

10/21/2005 | San Francisco Chronicle · Wall Street Journal, The

FDA granted permission to doctors at Stanford University Medical Center to transplant immature neural cells into the brains of six children with Batten disease, a degenerative, fatal illness. If approved by an internal Stanford review board, the transplant aims to have the immature cells grow into mature brain cells capable of producing a missing enzyme, a treatment that has shown promise in Batten-afflicted mice. Stem Cells, the biotech firm that developed the treatment, hopes the trial will demonstrate the efficacy and safety of the transplant.

View Full Article in:

San Francisco Chronicle · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA